CSPC Pharmaceutical Group Announces Discloseable FX Swap and Forward Contracts with ICBC
Key Developments
- CSPC Zhongqi, a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited, has entered into major foreign exchange (FX) contracts with the Industrial and Commercial Bank of China (ICBC).
- The deals include one FX Swap Contract and two FX Forward Contracts, all aimed at actively managing USD/RMB currency exposure in the group’s regular treasury operations.
- The Second FX Forward Contract, when aggregated with the previous contracts, triggered a “discloseable transaction” under the Hong Kong Stock Exchange Listing Rules, as one of the applicable percentage ratios exceeded 5% but remained below 25%.
- Shareholder approval is not required for these transactions, but disclosure and reporting are mandatory under Chapter 14 of the Listing Rules.
Contract Details
1. FX Swap Contract
- Date Signed: 16 June 2026
- Near Leg (16 June 2026): CSPC Zhongqi sells USD134,000,000 and buys RMB905,411,200 at prevailing market rates.
- Far Leg (16 September 2026): CSPC Zhongqi buys back USD134,000,000 and sells RMB899,595,600 at a pre-agreed rate.
- Security Deposit: USD3,189,200 to be placed with ICBC.
2. FX Forward Contracts
- First FX Forward Contract (17 July 2026): CSPC Zhongqi to buy USD120,000,000 by paying RMB814,260,000 on 18 December 2026.
Security Deposit: USD3,924,000. - Second FX Forward Contract (22 July 2026): CSPC Zhongqi to buy USD90,000,000 by paying RMB612,000,000 on 25 November 2026.
Security Deposit: USD2,943,000. - Settlement will occur at pre-agreed forward rates, determined based on ICBC market quotes at contract inception.
Risk Management and Security Terms
- If the floating loss on any transaction reaches 80% of the initial security deposit, ICBC can require CSPC Zhongqi to top up the deposit.
- ICBC retains the right to adjust deposit amounts if market risk conditions change.
- All transactions are funded internally by the Group, indicating no external financing or dilution risk.
Strategic Rationale and Potential Share Price Impact
- CSPC’s main operations are in RMB, but some subsidiaries hold USD liabilities and cash balances. These contracts are designed to hedge against USD/RMB volatility, reducing potential FX losses and safeguarding financial stability.
- By locking in exchange rates, the company is protecting itself against adverse currency moves, which could be significant in a volatile FX environment.
- This proactive treasury action could be viewed positively by investors concerned about RMB depreciation or USD volatility, providing greater earnings visibility and risk management.
- The Board considers these contracts to be on normal commercial terms, fair, reasonable, and in the best interests of shareholders.
Parties Involved
- CSPC Pharmaceutical Group Limited: Leading PRC pharmaceutical group, listed in Hong Kong.
- CSPC Zhongqi: Wholly-owned, PRC-based R&D subsidiary.
- ICBC: Leading PRC commercial bank, acting through its Shijiazhuang branch (Independent Third Party).
Board and Governance
- The Board affirms that ICBC and its ultimate beneficial owners are independent of CSPC and its connected persons.
- The Board comprises key executive and independent directors, ensuring robust oversight.
Potential Share Price Sensitivity
- The notional size of the FX contracts (aggregate of over USD300 million) is material relative to normal treasury activities, and could influence financial results if currency volatility is significant.
- Any unforeseen currency swings or failure to manage margin calls could impact the Group’s cash flow or earnings.
- However, the proactive hedging and internal funding should limit downside risk and may be viewed as prudent risk management by investors.
Conclusion
Investors should note: CSPC Pharmaceutical Group is taking significant steps to manage currency risk, using substantial FX contracts with ICBC as part of its ordinary course of business. While these contracts are not expected to require shareholder approval, their size and risk management features could have a material impact on future financial performance, especially in a volatile FX market.
Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consider their own circumstances and consult professional advisers before making investment decisions. The author and publisher accept no liability for any loss arising from reliance on this article.
石藥集團公佈與工商銀行重大外匯掉期及遠期合約
重點摘要
- 石藥集團全資子公司中奇製藥，已與中國工商銀行（ICBC）簽訂多份主要外匯合約，包括一份外匯掉期及兩份遠期外匯合約。
- 合約目的是在集團日常財資管理活動中，積極管理美元/人民幣匯率風險。
- 第二份遠期合約與前述合約合併計算後，觸及香港上市規則「可披露交易」門檻（適用比率超過5%但低於25%）。
- 股東無須批准本次交易，但需按上市規則作出公告及報告。
合約詳情
1. 外匯掉期合約
- 簽署日期：2026年6月16日
- 近端（2026年6月16日）： 賣出美元1.34億，買入人民幣9.0541億元。
- 遠端（2026年9月16日）： 買回美元1.34億，賣出人民幣8.9959億元。
- 保證金：3,189,200美元。
2. 遠期外匯合約
- 第一份遠期合約（2026年7月17日）：中奇將於2026年12月18日支付人民幣8.1426億元購買1.2億美元。
保證金：3,924,000美元。 - 第二份遠期合約（2026年7月22日）：中奇將於2026年11月25日支付人民幣6.12億元購買9,000萬美元。
保證金：2,943,000美元。 - 結算將按合約簽訂時ICBC報價的預定遠期匯率執行。
風險管理及保證金條款
- 若任何交易的浮動虧損達到初始保證金的80%，ICBC有權要求中奇補倉。
- ICBC亦可因應市場風險情況調整保證金金額。
- 全部交易均以集團內部資金提供，無外部融資或攤薄風險。
戰略原因及潛在股價影響
- 集團主營業務以人民幣結算，但部分子公司持有美元負債及現金。合約旨在對沖美元/人民幣波動，減少外匯損失，保障財務穩定。
- 鎖定匯率，有效對沖市場波動，降低潛在損失。
- 此舉反映集團積極財務管理，有助提升盈利可見度及風險控制，對投資者屬正面訊號。
- 董事會認為合約條款公平合理，符合公司及股東整體利益。
合約各方簡介
- 石藥集團：中國領先醫藥集團，港股上市。
- 中奇製藥：集團全資研發子公司，位於中國。
- ICBC：中國最大商業銀行之一，以石家莊分行為交易對手，為獨立第三方。
董事會及管治
- 董事會確認ICBC及其實益擁有人與石藥集團無關聯。
- 董事會成員包括多位執行及獨立非執行董事，監管嚴謹。
潛在股價敏感因素
- 合約名義金額（逾3億美元）屬集團財資活動中較大規模，若匯市劇烈波動，對財務表現或有影響。
- 若因市況劇變導致需大額補倉或合約管理失誤，或會影響集團現金流或盈利。
- 然而，積極對沖及內部資金運作，有助減低下行風險，屬審慎管理。
總結
投資者請留意：石藥集團正透過與ICBC簽訂大額外匯合約，積極管理匯率風險。雖然合約無需股東批准，但規模及風險控制措施，對集團未來財務表現或有實質影響，尤其在匯市波動時。
免責聲明：本文僅供參考，不構成任何投資建議。投資者應根據自身情況，諮詢專業意見後作出投資決定。作者及出版方對據此資料造成的任何損失概不負責。
